Luminita Pricop
- Immunology top 0.5%
- Rheumatology top 0.2%
- Hematology top 0.5%
- Radiology, Nuclear Medicine and Imaging top 2%
- Molecular Biology
- Co-authors
- Iain B. McInnesPhilip J. MeaseShephard MpofuProton RahmanDésirée van der HeijdeBruce KirkhamJane E. SalmonHanno B. Richards
- Topics
- Spondyloarthritis Studies and Treatments (74 papers)Psoriasis: Treatment and Pathogenesis (62 papers)Rheumatoid Arthritis Research and Therapies (49 papers)
- Cited by
- RheumatologyImmunologyHematology
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Luminita Pricop
112 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Immunology 3.5k
- Rheumatology 2.7k
- Hematology 1.6k
- Radiology, Nuclear Medicine and Imaging 696
- Molecular Biology 531
Countries citing papers authored by Luminita Pricop
This map shows the geographic impact of Luminita Pricop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luminita Pricop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luminita Pricop more than expected).
Fields of papers citing papers by Luminita Pricop
This network shows the impact of papers produced by Luminita Pricop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luminita Pricop. The network helps show where Luminita Pricop may publish in the future.
Co-authorship network of co-authors of Luminita Pricop
This figure shows the co-authorship network connecting the top 25 collaborators of Luminita Pricop. A scholar is included among the top collaborators of Luminita Pricop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luminita Pricop. Luminita Pricop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 26 | |
| 3 | 20 | |
| 4 | 45 | |
| 5 | Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis | 1 |
| 6 | 13 | |
| 7 | 27 | |
| 8 | SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: LONG-TERM (4-YEAR) DATA FROM A PHASE 3 STUDY | 1 |
| 9 | 2 | |
| 10 | Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study | 1 |
| 11 | Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study | 2 |
| 12 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study | 12 |
| 13 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing | 19 |
| 14 | Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | 16 |
| 15 | Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial | 12 |
| 16 | Recent contributions to the scientific substantiation of the gene theory of sexuality in Galinaceae. | 1 |
| 17 | 81 | |
| 18 | 12 | |
| 19 | 55 | |
| 20 | 191 |
About Luminita Pricop
Luminita Pricop is a scholar working on Rheumatology, Hematology and Immunology, having authored 115 papers that have together received 4.7k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (74 papers), Psoriasis: Treatment and Pathogenesis (62 papers) and Rheumatoid Arthritis Research and Therapies (49 papers). The work is most often cited by research in Rheumatology (2.7k citations), Immunology (3.5k citations) and Hematology (1.6k citations). Luminita Pricop has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Iain B. McInnes, Philip J. Mease, Shephard Mpofu, Proton Rahman, Désirée van der Heijde, Bruce Kirkham, Jane E. Salmon, Hanno B. Richards, Peter Nash and R. Landewé. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.